|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PXMP2 |
Gene summary for PXMP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PXMP2 | Gene ID | 5827 |
| Gene name | peroxisomal membrane protein 2 | |
| Gene Alias | MPV17L3 | |
| Cytomap | 12q24.33 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9NR77 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5827 | PXMP2 | LZE20T | Human | Esophagus | ESCC | 4.76e-03 | 1.34e-01 | 0.0662 |
| 5827 | PXMP2 | LZE22T | Human | Esophagus | ESCC | 1.27e-02 | 3.70e-01 | 0.068 |
| 5827 | PXMP2 | LZE24T | Human | Esophagus | ESCC | 7.39e-11 | 2.98e-01 | 0.0596 |
| 5827 | PXMP2 | P1T-E | Human | Esophagus | ESCC | 8.50e-07 | 3.29e-01 | 0.0875 |
| 5827 | PXMP2 | P2T-E | Human | Esophagus | ESCC | 2.00e-57 | 1.23e+00 | 0.1177 |
| 5827 | PXMP2 | P4T-E | Human | Esophagus | ESCC | 6.60e-33 | 7.45e-01 | 0.1323 |
| 5827 | PXMP2 | P5T-E | Human | Esophagus | ESCC | 1.37e-25 | 5.65e-01 | 0.1327 |
| 5827 | PXMP2 | P8T-E | Human | Esophagus | ESCC | 3.58e-25 | 4.24e-01 | 0.0889 |
| 5827 | PXMP2 | P10T-E | Human | Esophagus | ESCC | 1.61e-32 | 5.48e-01 | 0.116 |
| 5827 | PXMP2 | P11T-E | Human | Esophagus | ESCC | 5.21e-11 | 4.72e-01 | 0.1426 |
| 5827 | PXMP2 | P12T-E | Human | Esophagus | ESCC | 1.43e-20 | 3.48e-01 | 0.1122 |
| 5827 | PXMP2 | P15T-E | Human | Esophagus | ESCC | 5.44e-13 | 2.86e-01 | 0.1149 |
| 5827 | PXMP2 | P16T-E | Human | Esophagus | ESCC | 2.68e-26 | 5.74e-01 | 0.1153 |
| 5827 | PXMP2 | P17T-E | Human | Esophagus | ESCC | 8.26e-12 | 4.24e-01 | 0.1278 |
| 5827 | PXMP2 | P19T-E | Human | Esophagus | ESCC | 4.24e-05 | 4.72e-01 | 0.1662 |
| 5827 | PXMP2 | P20T-E | Human | Esophagus | ESCC | 2.41e-15 | 3.50e-01 | 0.1124 |
| 5827 | PXMP2 | P21T-E | Human | Esophagus | ESCC | 7.92e-69 | 1.36e+00 | 0.1617 |
| 5827 | PXMP2 | P22T-E | Human | Esophagus | ESCC | 3.44e-23 | 4.53e-01 | 0.1236 |
| 5827 | PXMP2 | P23T-E | Human | Esophagus | ESCC | 5.71e-21 | 5.13e-01 | 0.108 |
| 5827 | PXMP2 | P24T-E | Human | Esophagus | ESCC | 1.22e-17 | 3.08e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041467 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
| hsa0414612 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
| hsa041462 | Liver | Cirrhotic | Peroxisome | 36/2530 | 82/8465 | 4.79e-03 | 1.74e-02 | 1.07e-02 | 36 |
| hsa041463 | Liver | Cirrhotic | Peroxisome | 36/2530 | 82/8465 | 4.79e-03 | 1.74e-02 | 1.07e-02 | 36 |
| hsa041464 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa041465 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa041466 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
| hsa0414611 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PXMP2 | SNV | Missense_Mutation | novel | c.171N>T | p.Lys57Asn | p.K57N | Q9NR77 | protein_coding | tolerated(0.05) | benign(0.17) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PXMP2 | SNV | Missense_Mutation | c.267C>G | p.Phe89Leu | p.F89L | Q9NR77 | protein_coding | tolerated(0.18) | benign(0.005) | TCGA-MY-A5BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PXMP2 | SNV | Missense_Mutation | rs746666562 | c.346G>A | p.Val116Ile | p.V116I | Q9NR77 | protein_coding | tolerated(1) | benign(0.001) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PXMP2 | SNV | Missense_Mutation | rs765325030 | c.340N>T | p.Arg114Cys | p.R114C | Q9NR77 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| PXMP2 | SNV | Missense_Mutation | c.562G>A | p.Ala188Thr | p.A188T | Q9NR77 | protein_coding | tolerated(0.44) | benign(0.027) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| PXMP2 | SNV | Missense_Mutation | rs200781916 | c.176N>A | p.Arg59Gln | p.R59Q | Q9NR77 | protein_coding | tolerated(0.51) | benign(0.005) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PXMP2 | deletion | Frame_Shift_Del | novel | c.178delN | p.Glu62LysfsTer12 | p.E62Kfs*12 | Q9NR77 | protein_coding | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| PXMP2 | SNV | Missense_Mutation | rs746666562 | c.346G>A | p.Val116Ile | p.V116I | Q9NR77 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PXMP2 | SNV | Missense_Mutation | rs201360859 | c.421G>A | p.Ala141Thr | p.A141T | Q9NR77 | protein_coding | tolerated(0.49) | benign(0.143) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PXMP2 | SNV | Missense_Mutation | novel | c.356N>A | p.Pro119Gln | p.P119Q | Q9NR77 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |